Tadaaki Taniguchi serves as Chief Research & Development Officer at Astellas where he oversees a global team responsible for developing treatments with the potential to reshape expectations of health care. His responsibility covers multiple functions focused on developing innovative and patient-centric treatments and ensuring their appropriate and safe use throughout a product’s lifecycle.

Tadaaki joined Astellas in July 2022 and appointed CMO in October 2022 with more than 20 years of industry experience spanning research, development, and medical affairs. He has worked across a range of therapeutic areas, including oncology, diabetes and respiratory disease etc., to deliver transformational medicines to patients. Prior to joining Astellas, Tadaaki held multiple senior leadership roles in major multinational pharmaceutical companies in the U.S., Japan and China operating at global and regional levels.

Tadaaki completed a Ph.D. in Medicine at Imperial College London and earned his Doctor of Medicine degree from Tottori University in Japan. As a surgical oncologist, he spent 10 years working in clinics and research laboratories. The knowledge and experience he gained contributed to his unique perspective on how global pharmaceutical companies can innovate to deliver breakthrough science by rethinking approaches to medicine that change the way diseases are treated.

Education: Ph.D. in Medicine, Imperial College London; Ph.D. in Medicine, Tottori University; M.D., Tottori University

Organization in charge :
CRDO Office, Biopharma & Ophthalmology Development, Clinical Operations & Quantitative Science, Early Development & Translational Science, Oncology Development, Regulatory Affairs & Pharmacovigilance, Oncology Research, Cell & Gene Therapy Research, Innovation Lab, Primary Focus Lead Blindness & Regeneration, Primary Focus Lead Genetic Regulation, Primary Focus Immuno-Oncology, Primary Focus Lead Targeted Protein Degradation